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Summary The relationship between hormone replacement treatment (HRT) and breast cancer risk was
analysed using data from a case-control study conducted between June 1991 and February 1994 in six Italian
centres on 2569 patients aged below 75 with histologically confirmed breast cancer and 2588 controls admitted
to hospital for a wide spectrum of acute, non-neoplastic, non hormone-related diseases. Ever HRT use was
reported by 7.5% of cases and 7.5% of controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95%
confidence interval (CI), 0.9-1.5]. The risk increased with increasing duration of use: the ORs were 1.0 for use
lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. There was no clear pattern of risk with
reference to time since starting use, but the OR was significantly elevated (OR = 2.0, 95% CI 1.3-2.9) for
women who had stopped HRT within the last 10 years. No association was observed in those who had
stopped HRT more than 10 years ago (OR = 1.0). The increased OR for women who had stopped HRT
within the last 10 years was consistent across strata of identified covariates, and was significantly related to
duration of use. This study confirms the absence of a strong association between HRT and breast cancer risk,
although the risk estimate was above unity for women who had used HRT for 5 years or longer. However, the
risk was significantly elevated in the short to medium term after use, particularly for long-term use. This
short-term increased risk is consistent with an effect of HRT on one of the later stages of the process of breast
carcinogenesis. The flattening of risk with increasing time since stopping, and hence the absence of a long-term
cumulative excess in breast cancer risk after stopping HRT exposure. has relevant implications on individual
risk assessment and public health.
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A large number of epidemiological studies have been pub-
lished on the possible relationship between hormone replace-
ment treatment (HRT) and breast cancer risk. Although
overall the evidence does not support a consistent association
between ever use of HRT and subsequent breast cancer risk,
several issues remain unsettled (Henderson, 1989; Mack and
Ross, 1989; Steinberg et al., 1991; Mann, 1992; Brinton and
Schairer, 1993).
First, a few studies conducted on European populations
have found elevated relative risks (Hunt et al., 1987; Ewertz,
1988; Bergkvist et al., 1989; La Vecchia et al., 1992). Also,
among studies from North America, where the long-term use
of oestrogen replacement treatment is more frequent, most
investigations have found elevated risks among long-term
users (Henderson, 1989; Steinberg et al., 1991; Mann, 1992).
However, no consistent pattern of risk has emerged for
other time factors considered. A cohort study found that
current use may be particularly relevant (Colditz et al., 1990),
thus raising the possibility that HRT may have a late-stage
effect on breast carcinogenesis. However, the issue of time-
related factors in the HRT-breast cancer question remains
open to debate.
The type of preparation is another open question (Colditz
et al., 1992): the risk estimates, in fact, tend to be generally
higher in European studies (Hunt et al., 1987; Bergkvist et
al., 1989; La Vecchia et al., 1992), possibly because of the
different types of preparations used. In fact, following
heterogeneous prescribing patterns, synthetic oestrogens and
oestrogen-progestin combinations tend to be used in Europe,
while conjugated oestrogens are more commonly used in
North America (Mann, 1992).
Between 1983 and 1990, we conducted a case-control
study of HRT and breast cancer risk in the Greater Milan
area, Northern Italy, including 3037 cases and 2569 controls
(La Vecchia et al., 1986, 1992). Only 5% of cases and 3.5%
of controls, however, reported ever use of HRT, correspon-
ding to a relative risk (RR) of 1.3, of borderline significance,
and a moderate trend of increased risk with increasing dura-
tion of use (RR= 1.5 for longest use).
The prevalence of use of HRT, however, differs in various
areas of the country, and has increased over recent years.
Thus, to provide updated information on the HRT-breast
cancer issue in Italy, we considered data from a cooperative
case-control study of breast cancer conducted between 1991
and 1994 in six different areas of the country.
Subjects and methods
The data were derived from a case-control study of breast
cancer, conducted between June 1991 and February 1994 in
six Italian areas: Greater Milan, the provinces of Pordenone
and Gorizia, the urban area of Genoa, the province of Forli,
in northern Italy, the province of Latina in central Italy, and
the urban area of Naples, in southern Italy. The same struc-
tured questionnaire and coding manual were used in all study
centres, and all interviewers were centrally trained and tested
for reliability and reproducibility. On average, less than 4%
of cases and controls approached for interview refused to
participate.
Cases were women with incident (i.e. diagnosed within the
year before interview) histologically confirmed breast cancer,
admitted to the major teaching and general hospitals in the
areas under surveillance. A total of 2569 cases aged 23-74
years (median age 55 years) were included in the present
analysis.
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Controls were women residing in the same geographical
areas and admitted for acute conditions to the same network
of hospitals where cases had been identified. Women were
not included if they had been admitted for gynaecological,
hormonal or neoplastic diseases. A total of 2588 controls
aged 20-74 years (median age 56 years) were interviewed.
They were admitted to hospital for a wide spectrum of acute
diseases unrelated to known or potential risk factors for
breast cancer. Of these, 22% had traumatic conditions
(mostly fractures and sprains), 32% non-traumatic
orthopaedic disorders (mostly low back pain and disc
disorders), 16% were admitted for acute surgical conditions
(mostly abdominal, such as acute appendicitis or strangulated
hernia), 18% had eye diseases (mostly cataract and retinal
detachment) and 12% miscellaneous other illnesses, such as
ear, nose and throat and dental disorders.
The structured questionnaire included information on per-
sonal characteristics and habits, education and other socio-
economic factors, general lifetime habits, such as smoking,
alcohol and coffee consumption, a validated food frequency
consumption section, a few indicators of physical activity,
gynaecological and obstetric data, related medical history
and history of lifetime use of oral contraceptives, hormonal
replacement therapies in menopause, and female hormone
preparations for other indications, including time and dura-
tion of each episode of use and brand name, whenever
available. Lists of the most common female hormone
preparations (covering over 90% of the market over the last
two decades) were provided to assist recall, whenever
indicated. All interviews for cases and controls were con-
ducted in hospital.
Data analysis
Odds ratios (ORs) of breast cancer, and the corresponding
95% confidence intervals (CIs) for various measures of HRT
use were derived using unconditional multiple logistic regres-
sion, fitted by the method ofmaximum likelihood (Baker and
Nelder, 1978; Breslow and Day, 1980), including (i) terms for
study centre and age in quinquennia only and (ii) terms for
study centre, age, education, marital status, family history of
breast cancer, history of benign breast disease, parity and age
at first birth, age at menarche, type of menopause and age at
menopause.
Results
Table I gives the distribution of breast cancer cases and the
comparison group according to age and other major
identified covariates. There was no difference for marital
status, but cases were more educated, tended to report earlier
menarche and later menopause and were less frequently mul-
tiparous and in premenopause. They also reported later first
birth and more frequently family history of breast cancer and
personal history of benign breast diseases. All these factors
were considered potential confounders for the HRT-breast
cancer analysis, and hence were included in multiple logistic
regression equations.
Table II considers various measures of HRT use in the
overall dataset. The same proportion of cases and controls
(7.5%) reported ever HRT use; thus, the age-adjusted OR
was 1.0 and the multivariate OR was 1.2 (95% CI 0.9-1.5).
The risk increased with duration of use: the multivariate ORs
were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years
and 1.5 for 5 years or more. The trend in risk was of
borderline significance. There was no clear pattern of risk
with time since first HRT use, since the point estimates were
1.2 for use started within 10 years, 1.3 for 10-14 years and
1.1 for 15 years or more. In contrast, when time since last use
was considered, the OR was significantly elevated among
women who had stopped use within the last 10 years
(OR = 2.0, 95% CI 1.3-2.9), but not among those who had
been stopped for 10 years or more (OR= 1.0) or among
current users (OR = 0.8).
Table I Distribution of2569 cases ofbreast cancer and 2588 controlse
according to age, study centre and selected covariates, Italy.
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Cases Controls
No. (%0) No. (0%o
Age
<35
35-44
45-54
55-64
65-74
Study Centre
Pordenone Gorizia
Milan
Genoa
Forli
Rome Latina
Naples
Education (years)
<7
7-11
12
Unknown
Marital status
Never mamred
Ever married
Age at menarche (years)
<13
13-14
>15
Parity
Nulliparous
I-2 -3
Age at first birthb (years)
<25
> 25
Menopausal status
Pre in
Post
Age at menopause
< 50 years
> 50 years
Type of menopause
Natural
Surgical or other
Family history of breast cancer
No
Yes
History of benign breast disease
87
383
772
799
528
1046
585
290
212
178
258
(3.4)
(14.9)
(30.1)
(31.1)
(20.6)
(40.7)
(22.8)
(11.3)
(8.3)
(6.9)
(10.0)
1259 (49.0)
714 (27.8)
582 (22.7)
14 (0.5)
140 (5.4)
332 (12.8)
692 (26.7)
804 (31.1)
620 (24.0)
1015 (39.2)
623 (24.1)
310 (12.0)
213 (8.2)
178 (6.9)
249 (9.6)
1569 (60.6)
642 (24.8)
354 (13.7)
23 (0.9)
230 (9.0) 233 (9.0)
2339 (91.1) 2355 (91.0)
1123 (43.7)
1079 (42.0)
363 (14.1)
402 (15.7)
1567 (61.0)
600 (23.4)
1068 (41.3)
1098 (42.4)
419 (16.2)
380 (14.7)
1417 (54.8)
791 (30.6)
902 (35.1) 1179 (45.6)
1265 (49.2) 1029 (39.8)
986 (38.4) 842 (32.5)
1578 (61.4) 1745 (67.4)
641 (25.0)
933 (36.3)
1299 (50.6)
279 (10.9)
2270 (88.4)
299 (11.6)
843 (32.6)
899 (34.7)
1328 (51.3)
410 (15.8)
2453 (94.8)
135 (5.2)
No 2262 (88.1) 2346 (90.7)
Yes 307 (11.9) 242 (9.3)
'For some variables, the sum of strata does not add up to the total
because of missing values. bParous women only.
Selected types of preparation are considered in Table III.
The OR for ever vs never users was 1.3 for users of con-
jugated oestrogens only, 0.9 for ever users of other (mainly
synthetic) oestrogens and 1.0 for users of other miscellaneous
or undefined (including most women with short-term use)
HRT. Only ten subjects (six cases and four controls) reported
combined oestrogen-progestin therapy, corresponding to an
OR of 1.6. There was no significant heterogeneity in the use
of various preparations between cases and controls. Absolute
numbers were too limited for analyses of the risk of various
hormone prescriptions in current users only, or in strata of
duration, recency and latency of use.
The pattern of risk for time since last HRT use (< 10 and
) 10 years) is further considered in Table IV across strata of
selected covariates. The risk estimates were consistently
above unity for recent use across strata of age, parity and
family history of breast cancer. The association was appar-Hnnn repaam _unu and o1
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Table H Distribution of 2569 breast cancer cases and 2588 controls, odds ratios (OR) and 95%
confidence intervals (CIs) according to various measures ofhormone replacement treatment (HRT)
use, Italy, 1991-94
Cases Controls OR (95% CI)
No. (%) No. (%) OR]a OR?
HRT use
Never 2376 (92.5) 2395 (92.5) ib ib
Ever 193 ( 7.5) 193 ( 7.5) 1.0 (0.8-1.3) 1.2 (0.9-1.5)
Duration of HRT use (years)
< 1 91 (3.5) 98 (3.8) 1.0 (0.7-1.3) 1.0 (0.8-1.4)
1 -4 73 (2.8) 66 (2.6) 1.1 (0.8-1.6) 1.3 (0.9-1.9)
27 (1.1) 23 (0.9) 1.3 (0.7-2.2) 1.5 (0.8-2.6)
Unknown 2 (0.1) 6 (0.2) - -
Time since first HRT use (years)
<10 84 (3.3) 70 (2.7) 1.2 (0.8-1.6) 1.2 (0.9-1.8)
10-14 33 (1.3) 29 (1.1) 1.2 (0.7-2.0) 1.3 (0.8-2.2)
15 76 (3.0) 94 (3.6) 0.9 (0.7-1.2) 1.1 (0.8-1.5)
Time since last HRT use (years)
Current users 27 (1.0) 32 (1.2) 0.8 (0.5-1.4) 0.8 (0.5-1.4)
<10 years 78 (3.0) 44 (1.7) 1.8 (1.2-2.6) 2.0 (1.3-2.9)
10 86 (3.3) 111 (4.3) 0.8 (0.6-1.1) 1.0 (0.7-1.3)
Unknown 2 (0.1) 6 (0.2)
aEstimates from unconditional multiple logistic regression models including term for age, study
centre (ORI), plus marital status, education, body mass index, age at menarche, nulliparity, age at
first birth, menopausal status, age atmenopause, typeofmenopause,historyofbenignbreastdisease
and family history of breast cancer (OR2). bReference category. 'X2, trend = 3.62, P_0.05.
Table M Odds ratiosa (ORs) and 95% confidence intervals (CIs) of
breast canceraccording to ever use ofvariouspreparations ofhormone
replawement treatment, Italy, 1991-94
Type ofpreparation Cases Controls OR (95% CI)
Never users 2376 2395 1b
Conjugated oestrogens 30 27 1.3 (0.8-1.6)
Other oestrogens only 32 41 0.9 (0.7-1.4)
Oestrogens and progestins 6 4 1.6 (0.4-6.3)
Miscellaneous, other
or undefined 125 121 1.0 (0.8-1.5)
'Estimates from unconditional multiple logistic regression models,
including terms for age, study centre, education, body mass index,
parity, ageatmenopauseandfamilyhistoryofbreastcancer. bReference
category.
ently stronger in less educated women, in those of higher
body mass index and in those reporting later first birth and
menopause, but not history ofbenign breast disease. None of
the interaction terms, however, was significant. Likewise,
there was no evidence of interaction with alcohol drinking,
any other dietary factor considered-including a measure of
total fat and total calorie intake-and cigarette smoking (data
not shown). There was no evidence of association between
HRT use stopped for 10 or more years and breast cancer
risk.
Table V considers the interaction between time since last
use and duration of HRT use. For women who had stopped
using HRT within the last 10 years, the ORs were 1.4 for use
of less than 5 years and 1.7 for use lasting 5 years or more,
and the trend in risk was of borderline significnce. In con-
trast, there was no pattern of risk with duration of HRT use
for women who had stopped for 10 years or more.
The present study confirms the absence of strong association
between menopausal replacement treatment and breast
cancer risk, although the risk estimate was above unity in
women who had used HRT for 5 years or longer. In a sense,
its major value and originality derives from the study popula-
tion. In fact, this is one of the few available European
studies, and several investigations based on European
populations (Hunt et al., 1987; Ewertz 1989; Bergkvist et al.,
Table IV Odds ratiosa ofbreast canceraccording to time since last use
of hormone replacement treatment as compared with never users in
strata of selected covariates, Italy, 1991-94
Tine since last use (years)
Strata <O 10JO
Age (years)
50-59 1.4 0.6
60-79 2.8 1.2
Education (years)
<7 2.1b 0.9
> 7 1.0 1.0
Body mass index (kg m-)
<25 1.3 1.1
25 1.9 0.8
Age at menarche (years)
< 13 1.8b 0.9
. 13 2.0b 1.0
Parity
Nulliparous 1.5 0.8
1-2 1.4 1.0
)3 1.5 1.0
Age at first birth (years)
<25 1.2 1.2
>25 1.9" 1.0
Family history of breast cancer
No 1.5 1.0
Yes 3.7 0.9
History of benign breast disease
No 1.7b 0.9
Yes 1.0 0.8
Type ofmenopause
Natural 1.8b 1.0
Surgical or other 2.6b 0.9
Age at menopause (years)
<50 1.6 0.9
> 50 2.4b 1.4
'Estimates from unconditional multiple logistic regression models
including terms for age, study centre, education, body mass index,
parity, age atmenopauseandfamilyhistoryofbreast cancer. bp<0.05.
1989), including a previous Italian one (La Vecchia et al.,
1992), tended to support the existence of an association
between HRT and breast cancer risk, which could be explain-
ed in terms either of selection of menopausal replacementI.MP le m mbaIN- aNWhrudicw
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Table V Odds ratos' of breast cancer acordig to duration of
hormone replacement treatment (HRT) and time since last use as
compared with nev users, Italy, 1991-1994
Tire sbce last HRT use (years)
Duration (years) <10 > 10
<5 1.4 (1.0-2.0) 1.0 (0.7-1.3)
>,,5 1.7 (0.8-3.7)b 1.2 (0.5-2.9)
'Estimates from anunconditional logisticregression modelincluding
terms forage, studycentre, martal status, ducatuon, bodymassindex,
ageatmenarche,nullparity,ageatfirstbirth,menopausalstatus,ageat
menopause, type of menopause, history ofbenign breast disea and
family history ofbreast cancer. bX,2, tnd = 3.71, P=0.05.
treatment users or of different compositions of prearations
used in Europe (with a higher prevalence of synthetic oes-
trogens and oestrogen-progestn preparations in Europe) and
North America, or both.
However, there was an elevated risk for women who had
recently stopped HRT use, and a trend with duration which
was resticted to this subgroup. This is consiset with the
elevated risk observed in several sudies, lrgely based on
recent long-term use (Henderson, 1989; Steinberg et al.,
1991). A cohort study, in particular, found that current use
was specifically related to breast cancer risk (Colditz et al.,
1990).
This short-term increased risk is also rted in the pat-
tern of breast cancer risk observed after a full-time preg-
nancy or suggested after stopping oral contraceptive use,
with a short-term elevated risk that tends to lewl off or
reverse after 5-10 years (Bruzzi et al., 1988; La Vecchia et
al., 1990). This short-term effect is consistent across strata of
major identified covariates. In terms of the mulistage model
ofcarcinogeness, this would imply that HRT has a late-stage
effect on breast carcinogenesis (Day and Brown, 1980), as on
other female hormone-related neoplasns, such as endomet-
rial cancer (La Vecchia et al., 1984). In terms ofpublic health
implications, these results suggest that the elevated breast
cancer risk is restricted to the short period after stopping use,
in the absence of a long-term, and hence a cumulative, excess
risk after stopping HRT use.
In this study, however, there was no excess risk for current
users. If not due to chance, this may be attributable to the
shorter duration in current users (who had not yet complee
their period of use) or to some selection anisms, which
may lead women at high risk of breast cancer to withdraw
from HRT use.
Although there was no significnt interaction between
exogenous oestrogen use and age at dia is, there was
some suggestion of higher risk in the elderly, which is consis-
tent with the biological decine in endogenous hormones with
age (Cauley et al., 1989; Brinton and Schairer, 1993), as well
as with data from other case-control studies (Brinton et al.,
1986; Wmgo et al., 1987; Palmer et al., 1991; Kaufman et al.,
1991). Along a similar line of reasoning (Brinton and
Schairer, 1993), the OR was somewhat (though not
significantly) higher in women with surgical menopause than
in those with natural menopause. No meaningful interactions
or subgroup effect were observed with any of the other
variables considel, such as family history of breast cancer,
body mass index or alcohol drinking, which have been
debated in the past (Brinton and Schairer, 1993).
Most of the limitations and strengths of this study are
common to other hospital-based case-control studies (Mantel
and Haenszel, 1959). Thus, although this study was not
population based, cases were identified in the major teaching
and general hospitals ofthe areas under surveillance, lmiting
the possibility of selection bias. Still, some selecfion bias may
be related to the definition ofthe comparison group. For this
reason, only acute conditions, unrelated to known or poten-
tial risk factors for breast cancer, or to correlates of HRT
use in this population (Parazzini et al., 1993), were included
in the comparison group. Further, the hospital-based design
may improve the comparability of drug recall by cases and
controls, and - of specific interest to this study - the
participation of cases and controls was practically complete.
The potential confounding effect of several covariates was
allowed for in the analysis, but did not have an appreciable
impact on any of the relative risk estimates. Indeed, the
multivariate relative risk estimates were systematically higher
than the age-adjusted ones, suggesting that unadjusted values
were somewhat, although moderately, underestimated. Of
greater concern, in the interpretation of this study, was the
low prevalnc of menopausal replacement treatment in this
Italian population, which not only hampered detailed
analysis of subgroups and interactions, but might have con-
cealed some residual selection mechanisms.
The small absolute numbers, particularly of users of oest-
rogen-progestn combinations, also precluded any meaning-
ful inference on different types of preparations. StilL there
was little indication in this dataset of association with any
scific type of preparation, or combination of treatments.
These limitations and potential problems notwithstanding,
it is unlikely that any selection, information or confounding
bias would have led to systematic and substantial underes-
tmation of the association between HRT and breast cancer
risk. Thus, these data help to better assess the pattern of
breast cancer risk for various time-related aspects of HRT
use in a southern European population.
In more general terms of risk asessment and implications
for presription, these data indicate that there is a moderate
increase in breast cancer in the short to medium term after
use, but are larly reassuring for the ultimate long-term
impact of HRT on breast carcinogenesis.
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